Iol Chemcials And Pharmaceuticals

IOL Chemicals and Pharmaceuticals, headquartered in India and operating in the Pharmaceutical Preparation Manufacturing industry, has disclosed its carbon emissions and climate commitments.

For the most recent reported year, 2025, IOL Chemicals and Pharmaceuticals's total emissions were approximately 144,265 tonnes CO2e. This includes Scope 1 emissions of about 45,025 tonnes CO2e, Scope 2 emissions of approximately 6,020 tonnes CO2e, and Scope 3 emissions of about 93,042 tonnes CO2e. In 2024, the company reported total emissions of approximately 164,057 tonnes CO2e, comprising Scope 1 emissions of around 49,521 tonnes CO2e, Scope 2 emissions of about 6,179 tonnes CO2e, and Scope 3 emissions of roughly 108,357 tonnes CO2e. For 2023, the total emissions were approximately 130,808 tonnes CO2e, with Scope 1 emissions of about 49,521 tonnes CO2e, Scope 2 emissions of about 6,179 tonnes CO2e, and Scope 3 emissions of around 108,357 tonnes CO2e. In 2022, total emissions were approximately 26,879 tonnes CO2e, with Scope 1 emissions of about 24,928 tonnes CO2e, Scope 2 emissions of about 1,171 tonnes CO2e, and Scope 3 emissions of around 779 tonnes CO2e.

IOL Chemicals and Pharmaceuticals has made significant climate commitments, with targets validated by the Science Based Targets initiative (SBTi). The company has a long-term net-zero target to reach net-zero greenhouse gas emissions across its value chain by FY2050.

For near-term reduction, IOL Chemicals and Pharmaceuticals commits to:

• Reduce absolute Scope 1 and 2 GHG emissions by 58.8% by FY2033, using FY2022 as a base year.
• Reduce absolute Scope 3 GHG emissions by 35% within the same timeframe.

For long-term reduction, the company aims to:

• Reduce absolute Scope 1 and 2 GHG emissions by 90% by FY2050, from a FY2022 base year.
• Reduce absolute Scope 3 GHG emissions by 90% within the same timeframe.

The target boundary includes land-related emissions and removals from bioenergy feedstocks.